EASTWOOD, Australia,
Jan. 5, 2022 /PRNewswire/ --
Bionomics Limited (Bionomics or Company), a
clinical-stage biopharmaceutical company, today announced the
issuance of 243,300 American Depositary Shares (ADSs), each
representing 180 ordinary shares of Bionomics, pursuant to the
exercise in full of the underwriters' option to purchase additional
ADSs in connection with the Company's previously announced initial
public offering in the United
States (the Offering). The ADSs were sold at a
public offering price of US$12.35 per
ADS.
The total gross proceeds from the Offering (including the
previously issued 1,622,000 ADSs) increased to approximately
US$23 million, before deducting
underwriting discounts and commissions and other offering expenses
payable by Bionomics. The ADSs began trading on the Nasdaq Global
Market on December 16, 2021, under
the ticker symbol "BNOX".
Evercore ISI and William Blair
acted as lead book-running managers for the Offering. Cantor,
Berenberg and H.C. Wainwright & Co. acted as book-running
managers for the Offering.
A registration statement relating to the securities sold in this
offering was declared effective by the U.S. Securities and Exchange
Commission on December 15, 2021. This
offering was made only by means of a prospectus under the U.S.
Securities Act of 1933. A copy of the final prospectus may be
obtained from the SEC at www.sec.gov, and from (i) Evercore Group
L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street,
35th Floor, New York, New York
10055, or by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com; or (ii) William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, or by telephone at
(800) 621-0687, or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Released on authority of the Company Secretary.
About Bionomics Limited
Bionomics is a clinical-stage biopharmaceutical developing
novel, allosteric ion channel modulators designed to transform the
lives of patients suffering from serious central nervous system
disorders with high unmet medical need. Bionomics is advancing its
lead product candidate, BNC210, an oral, proprietary, selective
negative allosteric modulator of the α7 nicotinic acetylcholine
receptor, for the acute treatment of Social Anxiety Disorder and
chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210,
Bionomics has a strategic partnership with Merck & Co., Inc.
(known as MSD outside the United
States and Canada) with two
drugs in early-stage clinical trials for the treatment of cognitive
deficits in Alzheimer's disease and other central nervous system
conditions.
www.bionomics.com.au
Factors Affecting Future Performance
This announcement contains "forward-looking" statements within
the meaning of the U.S. federal securities laws. Any statements
contained in this announcement that relate to prospective events or
developments, including, without limitation, statements related to
the Offering are deemed to be forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "projects,"
"forecasts," "will" and similar expressions are intended to
identify forward-looking statements. There are a number of
important factors that could cause actual results or events to
differ materially from those indicated by these forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events, or otherwise. Actual results could
differ materially from those discussed in this ASX
announcement.
View original
content:https://www.prnewswire.com/news-releases/bionomics-limited-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-in-the-united-states-301455083.html
SOURCE Bionomics Limited